12:00 AM
 | 
Dec 17, 2012
 |  BC Week In Review  |  Company News  |  Deals

Pernix Therapeutics, Somaxon deal

Specialty pharma Pernix will acquire Somaxon in stock deal that values Somaxon at $25 million. Somaxon shareholders will receive a number of Pernix shares based on the price...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >